What is ArriVent BioPharma, Inc.'s price / book?

ArriVent BioPharma, Inc. (AVBP) reported price / book of 3.1× in Q1 2026.

How has ArriVent BioPharma, Inc.'s price / book changed year-over-year?

ArriVent BioPharma, Inc.'s price / book increased by 1.4% year-over-year, from 3.1× to 3.1×.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

ArriVent BioPharma, Inc. AVBP Price / book

Price / book at other companies

Johnson & JohnsonJNJ

7.3×+2.1×

Syndax PharmaceuticalsSNDX

49.5×+44.6×

Nuvation BioNUVB

4.7×+3.2×

ImmunomeIMNM

4.2×+2.3×

Arcus BiosciencesRCUS

5.2×+3.6×

Erasca, Inc.ERAS

12.8×+11.8×

Other financials

Income statement

See full

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Balance sheet

See full

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Cash flow

See full

Operating cash flow-$41.9M+38.4%

Valuation

See full

Market cap$1.57B+62.1%

Enterprise value$1.51B+65.4%

Returns & leverage

See full

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Where this comes from

Calculated from ArriVent BioPharma, Inc.’s reported figures.

market cap/total stockholders equity=3.1×

Based on the most recent quarter.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s price / book?: ArriVent BioPharma, Inc. (AVBP) reported price / book of 3.1× in Q1 2026.
How has ArriVent BioPharma, Inc.'s price / book changed year-over-year?: ArriVent BioPharma, Inc.'s price / book increased by 1.4% year-over-year, from 3.1× to 3.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.